Christopher M. Olsen, PhD
- Pharmacology and Toxicology
MS, Texas Tech University, 1998
BA, Baylor University, 1994
- Brain Concussion
- Brain Injuries
- Brain Injury, Chronic
- Cocaine-Related Disorders
- Exploratory Behavior
- Opioid-Related Disorders
- Substance-Related Disorders
MCW Program / Core Facilities
- Neuroscience Research Center
Addiction is a chronically relapsing disorder that is strongly modulated by positive and negative environmental factors. Our lab (olsenlab.org) focuses on how these environmental factors can influence drug intake and drug seeking using rat and mouse models of addiction.
We have two major projects to investigate environmental factors and addiction:
Environmental modulation of drug seeking ensembles. Transgenic approaches are used to identify and manipulate cells that are engaged during drug seeking following intravenous drug self-administration. We are studying the effects of positive and negative environmental factors on drug seeking and the activity of cells within drug seeking ensembles.
The impact of mild traumatic brain injury (mTBI) on addiction and mesocorticolimbic function. This work is done in collaboration with Drs. Brain Stemper and Matthew Budde in the Department of Biomedical Engineering and Neurosurgery, respectively. We are examining the effects of mTBI on drug self-administration, drug seeking, and mesocorticolimbic function using diffusion tensor imaging (DTI) and functional connectivity.
Identification of neuronal ensembles involved in persistent drug seeking. TetTag (green) cells are those engaged during an initial drug seeking session, Fos+ (red) cells are those engaged during a second drug seeking session 2 weeks later.
Quantification of monocytes/microglia. Iba1+ (green) cells are surface rendered for complex analysis to examine long-lasting effect of mild traumatic brain injury on immune cells within the brain. Gray=nuclei (DAPI).
(Nawarawong NN, Slaker M, Muelbl M, Shah AS, Chiariello R, Nelson LD, Budde MD, Stemper BD, Olsen CM.) Eur J Neurosci. 2019 Aug;50(3):2101-2112.
(Muelbl MJ, Slaker ML, Shah AS, Nawarawong NN, Gerndt CH, Budde MD, Stemper BD, Olsen CM.) Sci Rep. 2018 07 02;8(1):9941.
(Pan J, Lee Y, Cheng G, Zielonka J, Zhang Q, Bajzikova M, Xiong D, Tsaih SW, Hardy M, Flister M, Olsen CM, Wang Y, Vang O, Neuzil J, Myers CR, Kalyanaraman B, You M.) iScience. 2018 May 25;3:192-207.
(Nelson LD, Furger RE, Ranson J, Tarima S, Hammeke TA, Randolph C, Barr WB, Guskiewicz K, Olsen CM, Lerner EB, McCrea MA.) J Neurotrauma. 2018 01 15;35(2):249-259.
(Helfand AI, Olsen CM, Hillard CJ.) Int J Mol Sci. 2017 Jul 27;18(8).
(Stemper BD, Shah AS, Chiariello R, Olsen CM, Budde MD, Glavaski-Joksimovic A, McCrea M, Kurpad SN, Pintar FA.) Ann Biomed Eng. 2016 Nov;44(11):3252-3265.
(Olsen CM, Liu QS.) Front Biol (Beijing). 2016 Oct;11(5):376-386.
(Muelbl MJ, Nawarawong NN, Clancy PT, Nettesheim CE, Lim YW, Olsen CM.) Psychopharmacology (Berl). 2016 Jul;233(14):2799-811.
(LD Nelson, RE Furger, J Ranson, S Tarima, TA Hammeke, C Randolph, WB Barr, K Guskiewicz, CM Olsen, EB Lerner, and MA McCrea.) Journal of Neurotrauma. (in press).
(Stemper B.D., Shah A.S., Budde M.D., Chiariello R., Wilkins N., Olsen C., Mehta P., Kurpad S.N., McCrea M., Pintar F.A. .) 2015 IRCOBI Conference Proceedings. 198-207.
(Stemper, BD, AS Shah, R Chiariello, CM Olsen, MD Budde, A Glavaski-Joksimovic, M McCrea, SN Kurpad, FA Pintar .) Annals of Biomedical Engineering. .
(Muelbl, MJ, NN Nawarawong, PT Clancy, CE Nettesheim, YW Lim, CM Olsen .) Psychopharmacology. .